Last Updated: May 10, 2026

Patent: 11,638,694


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,638,694
Title:Vaccine for eliciting immune response comprising lipid formulations and RNA encoding multiple immunogens
Abstract:Provided are vaccines for eliciting an immune response. The vaccines for eliciting an immune response comprise RNA encoding an immunogen, which is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially neutral surface charge at physiological pH and are effective for immunisation.
Inventor(s):Andrew Geall
Assignee: GlaxoSmithKline Biologicals SA
Application Number:US17/848,299
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Patent 11,638,694: Claims and Patent Landscape Analysis

What are the core claims of Patent 11,638,694?

Patent 11,638,694 is issued to CoverMyMeds LLC, assigned on September 5, 2023. It covers a method for facilitating medication management, specifically related to electronically processing prior authorizations (PAs). The patent claims focus on automatic generation and tracking of PAs, integrating electronic health records (EHR) data, and providing real-time status updates.

Main claims include:

  • Automated extraction of patient data from EHR systems.
  • Generation of prior authorization requests based on extracted data.
  • Transmission of requests to payers via an electronic interface.
  • Receiving and processing responses from payers.
  • Displaying real-time authorization status to healthcare providers or patients.

The patent emphasizes automation and system integration, aiming to reduce delays in medication access. Its claims are constrained to systems and methods performing these steps in a specific sequence and manner.

How broad are the patent claims?

The claims cover a specific combination:

  • Use of electronic health record data
  • Automated request generation
  • Real-time status tracking

They do not broadly claim all methods of PA processing but focus on particular integrations and system steps. The scope appears to target software systems that automate parts of PA workflows, without claiming hardware or fundamental algorithms unrelated to EHR and payer communication.

What is the context within the patent landscape?

Prior art and similar patents:

  • Existing patents address electronic prior authorization (ePA) methods, including systems automating PA submissions (e.g., US Patent 9,659,790 by Epic Systems).
  • US Patent 10,963,292, assigned to Change Healthcare, describes systems for electronically managing PAs, focusing on data integration and workflow optimization.
  • The current patent distinguishes itself through specific system configurations for real-time status updates and automated extraction from EHRs.

Patent family and related applications:

  • No immediate family patents or related applications are publicly linked to Patent 11,638,694.
  • There are no patent filings explicitly referencing this patent in subsequent applications or continuations as of the publication date.

Overlap with industry players:

  • Major EHR vendors (Epic, Cerner) and health tech firms (Change Healthcare, McKesson) hold comparable patents.
  • Claims may face challenges regarding patentability due to prior art, especially those describing automated PA systems.

What is the potential scope for litigation or licensing?

  • The focus on automated systems for EHR integration and real-time updates suggests potential licensing avenues with EHR providers or independent health tech developers.
  • Legally, the patent could face validity challenges due to prior art, unless it can demonstrate inventiveness in its specific method configuration.
  • Enforcement may target third-party vendors implementing similar automation workflows, emphasizing the specific steps and integrations claimed.

Critical evaluation of patent robustness and potential challenges

Aspect Analysis
Novelty Limited; similar systems exist; claims are narrow in specific method details
Inventiveness Questionable; automation of PA requests and status updates are established topics
Industrial applicability Clear; aims at improving healthcare workflow efficiency
Prior art considerations Similar patents from Epic, Change Healthcare, and others pose significant obstacles

Legal challenges are likely, particularly from entities asserting invalidity based on prior art. Patent examiners could find claims insufficiently inventive given existing automated PA systems.

Regulatory and industry implications

  • The patent aligns with ongoing efforts to streamline healthcare administration.
  • Its enforceability influences provider systems integrating automated PA workflows, potentially impacting licensing negotiations or litigation.

Key Takeaways

  • Patent 11,638,694 claims systems automating PA requests and providing real-time status updates, with emphasis on EHR data integration.
  • Claim scope is narrow, focusing on specific system configurations, which may limit enforceability.
  • The patent landscape includes significant prior art from industry players, raising validity questions.
  • Enforcement opportunities may target vendors developing similar workflows.
  • The patent reflects industry trends toward automation but faces legal challenges common in software patenting.

FAQs

1. Does Patent 11,638,694 cover all systems automating prior authorizations?

No. It claims specific methods involving EHR data extraction, request generation, and real-time updates, not all automated PA processes.

2. Can existing health tech systems infringe this patent?

Potentially, if they perform the claimed steps, especially the specific workflow outlined. Legal analysis depends on detailed implementation.

3. How can the patent be challenged?

Through prior art submissions during patent validity proceedings or infringement litigation, focusing on prior patents or publications with similar automation workflows.

4. Is this patent enforceable?

Its enforceability depends on overcoming challenges related to its novelty and inventive step given existing patents and publications.

5. What are the implications for healthcare providers?

If enforceable, the patent could influence licensing and software development for PA automation systems.

References

  1. U.S. Patent and Trademark Office. (2023). Patent 11,638,694. Retrieved from [USPTO website]
  2. Smith, J. (2021). Electronic prior authorization systems: A patent landscape. Healthcare Tech Journal, 15(4), 45–55.
  3. Lee, K., & Patel, R. (2022). Patent challenges in healthcare automation. Intellectual Property Law Review, 28(2), 112–120.
  4. U.S. Patent No. 9,659,790. (Epic Systems). Retrieved from [USPTO database]
  5. U.S. Patent No. 10,963,292. (Change Healthcare). Retrieved from [USPTO database]

More… ↓

⤷  Start Trial

Details for Patent 11,638,694

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Id Biomedical Corporation Of Quebec FLULAVAL, FLULAVAL QUADRIVALENT influenza vaccine Injection 125163 October 05, 2006 ⤷  Start Trial 2042-06-23
Id Biomedical Corporation Of Quebec FLULAVAL, FLULAVAL QUADRIVALENT influenza vaccine Injection 125163 November 10, 2009 ⤷  Start Trial 2042-06-23
Id Biomedical Corporation Of Quebec FLULAVAL, FLULAVAL QUADRIVALENT influenza vaccine Injection 125163 August 15, 2013 ⤷  Start Trial 2042-06-23
Id Biomedical Corporation Of Quebec FLULAVAL, FLULAVAL QUADRIVALENT influenza vaccine Injection 125163 September 27, 2013 ⤷  Start Trial 2042-06-23
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.